OPTIMA

Optimal treatment for patients with solid tumours in Europe through artificial intelligence

Summary

Advances in research mean that for many cancers, there are more treatment options than ever. Physicians face a growing number of diagnostic tests, treatments and guidelines, making it increasingly challenging to ensure each patient receives the right treatment.

The aim of OPTIMA is to harness the power of artificial intelligence to advance treatments and facilitate decision-making for physicians and patients with prostate, breast and lung cancer.

At the heart of OPTIMA will be Europe’s first interoperable, large scale oncology data and evidence generation platform with data from over 200 million people. The platform, which will be GDPR (General Data Protection Regulation) compliant, will host data sets, data analysis tools, federated learning tools, and artificial intelligence (AI) tools.

The project will use the platform to drive the generation of new knowledge by developing advanced analytics and AI models to identify, prioritise and fill the main knowledge gaps in prostate, breast and lung cancer, and propose improved clinical guideline recommendations. Finally, they will develop AI-based decision support tools that can help clinicians, together with their patients, make treatment decisions based on the leading clinical practice guidelines.

By designing the platform based on the needs of clinicians and patients, and by including the major guideline offices for prostate, breast and lung cancer, the project is well placed to have an impact care down the line.

Achievements & News

Participants

  Show participants on map
EFPIA companies
  • Abbvie Inc, North Chicago Il, United States
  • Amgen, Diegem, Belgium
  • Astrazeneca AB, Sodertaelje, Sweden
  • Bayer Aktiengesellschaft, Leverkusen, Germany
  • F. Hoffmann-La Roche AG, Basel, Switzerland
  • Pfizer Limited, Sandwich, United Kingdom
Universities, research organisations, public bodies, non-profit groups
  • Association Eisbm, Vourles, France
  • Deutsche Krebsgesellschaft Ev, Berlin, Germany
  • Erasmus MC, Rotterdam, Netherlands
  • European Respiratory Society, Lausanne, Switzerland
  • Fundacio Institut Universitari Pera La Recerca A L'Atencio Primaria De Salut Jordi Gol I Gurina, Barcelona, Spain
  • Helmholtz-Zentrum Dresden-Rossendorf Ev, Dresden, Germany
  • Institut De Cancerologie De L'Ouest, Angers, France
  • Ludwig-Maximilians-Universitaet Muenchen, Planegg, Germany
  • Lunds Universitet, Lund, Sweden
  • Lungs Europe, Bruxelles / Brussel, BelgiumThird-party
  • Organisation Europeenne Pour La Recherche Et Le Traitement Du Cancer Aisbl, Bruxelles / Brussel, Belgium
  • Queen Mary University Of London, London, United Kingdom
  • Tartu Ulikool, Tartu, Estonia
  • The University Court Of The University Of Aberdeen, Aberdeen, United Kingdom
  • Universita Degli Studi Di Firenze, Florence, Italy
  • Universita Vita-Salute San Raffaele, Milano, Italy
  • Universitat Wien, Wien, Austria
  • Universiteit Maastricht, Maastricht, Netherlands
  • University College London, London, United Kingdom
  • University of Oxford, Oxford, United Kingdom
  • Uppsala Universitet, Uppsala, Sweden
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Bdm Consulting, Larajasse, France
  • Gmv Soluciones Globales Internet Sau, Tres Cantos Madrid, Spain
  • Information Technology For Translational Medicine (Ittm) SA, Esch-Uelzecht, Luxembourg
  • Istituto Europeo Di Oncologia SRL, Milano, Italy
  • Mutabor Technologies GMBH, Hamburg, Germany
  • PNO Life Sciences & Health B.V., Rijswijk, Netherlands
  • Pno Innovation GMBH, Munchen, Germany
  • Smart Reporting GMBH, München, Germany
  • Stichting European Urological Foundation, Arnhem, Netherlands
  • Ydeal.Net Software Lda, Agoncida, Portugal
Patient organisations
  • European Lung Foundation, Sheffield, United Kingdom
Other companies
  • Helios Klinikum Emil Von Behring GMBH, Berlin, Germany

Participants
NameEU funding in €
Association Eisbm509 106
Bdm Consulting358 353
Deutsche Krebsgesellschaft Ev99 994
Erasmus MC700 259
European Cancer Patient Coalition (left the project)24 843
European Lung Foundation118 803
European Respiratory Society126 750
Fundacio Institut Universitari Pera La Recerca A L'Atencio Primaria De Salut Jordi Gol I Gurina200 416
Gmv Soluciones Globales Internet Sau744 354
Helmholtz-Zentrum Dresden-Rossendorf Ev684 000
Information Technology For Translational Medicine (Ittm) SA937 500
Institut De Cancerologie De L'Ouest90 000
Istituto Europeo Di Oncologia SRL50 000
Ludwig-Maximilians-Universitaet Muenchen40 000
Lunds Universitet71 000
Organisation Europeenne Pour La Recherche Et Le Traitement Du Cancer Aisbl3 000
Owkin France (left the project)41 731
Pno Innovation GMBH162 857
PNO Life Sciences & Health B.V.326 218
Queen Mary University Of London220 000
Region Uppsala (left the project)12 147
Smart Reporting GMBH398 250
Stichting European Urological Foundation1 092 405
Tartu Ulikool470 000
The University Court Of The University Of Aberdeen773 424
Universita Vita-Salute San Raffaele50 125
Universitat Wien433 130
Universiteit Maastricht412 500
University College London98 590
University of Oxford967 594
Uppsala Universitet67 875
Ydeal.Net Software Lda162 275
 
Third parties
NameFunding in €
Lungs Europe12 500
 
Total Cost10 459 999